Trial Search Results
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.
Stanford is currently not accepting patients for this trial.
- Drug: Cyclophosphamide
- Drug: Etoposide
- Drug: Melphalan
- Drug: Carmustine
- Drug: Filgrastim
- Stage II to III multiple myeloma, or progression after initial treatment of Stage I
disease; early or relapsed
- Age 18 to 75 years.
- Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.
- Patients with amyloidosis may be eligible for this trial, with approval by the
- Patients must have a Karnofsky performance status > 70%.
- Aspartate aminotransferase (AST) must be < 2 x upper limit of normal (ULN)
- Alanine aminotransferase (ALT) must be < 2 x ULN
- Total bilirubin < 2 mg/dL.
- Serum creatinine < 2.0 or 24-hour creatinine clearance ≥ 60 mL/min.
- Patients must be HIV-negative.
- Patients must provide signed, informed consent.
- Severe psychological or medical illness
- Prior autologous hematopoietic cell transplantation
- Lactating women
- Smoldering multiple myeloma,
- Monoclonal gammopathy of unknown significance or primary amyloidosis will be excluded
from this study
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study